Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dolutegravir Liquid Formulations vs Tablets in Healthy Adults
NCT03921723Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point at 72 hours, Area Under the Plasma Concentration Time Curve From Time Zero to Infinity at 72 hours and 1 more. Started May 2019; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03921723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921723.